Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05359861 · ClinicalTrials.gov registry record · Phase 2
Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
A Phase 2 study, sponsored by Coherus Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT05359861 is a Phase 2 study that has completed, run by Coherus Oncology. The registered enrollment target is 30 participants.
The verdict
NCT05359861, a Phase 2 study, has completed, sponsored by Coherus Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a Phase 2 trial composed of an open label Lead-In followed by a Randomized Phase designed to evaluate the efficacy and safety of SRF388 in combination with atezolizumab plus bevacizumab compared to placebo (inactive substance) in combination with atezolizumab plus bevacizumab in patients with first-line advanced or metastatic HCC.
Interventions
- DRUG Bevacizumab
- DRUG Placebo
- DRUG Atezolizumab
- DRUG SRF388
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-04-12 |
| Est. Completion | 2025-07-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05359861
The ClinicalTrials.gov registry entry for NCT05359861 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Coherus Oncology, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT05359861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05359861 about?
NCT05359861 is a clinical study titled "Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma". This is a Phase 2 trial composed of an open label Lead-In followed by a Randomized Phase designed to evaluate the efficacy and safety of SRF388 in combination with atezolizumab plus bevacizumab compared to placebo (inactive substance) in combination with atezolizumab plus bevacizumab in patients wit...
What is the current status of trial NCT05359861?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2022-04-12. Estimated completion is 2025-07-08.
What interventions are being tested in trial NCT05359861?
The interventions under investigation include: Bevacizumab (DRUG), Placebo (DRUG), Atezolizumab (DRUG), SRF388 (DRUG).
Who is sponsoring clinical trial NCT05359861?
This trial is sponsored by Coherus Oncology, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.